The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis

Technology in Cancer Research and Treatment - Tập 17 - 2018
Małgorzata Fuksiewicz1, Beata Kotowicz1, Andrzej Rutkowski2, Joanna Achinger-Kawecka3,4, Michał Wągrodzki5, M Kowalska1
1Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
2Department of Oncological Gastroenterology, Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland
3Faculty of Medicine, St Vincent's Clinical School, University of New South Wales, Darlinghurst, New South Wales, Australia
4Genomics and Epigenetics Division, Garvan Institute of Medical Research, Epigenetics Research Laboratory, Darlinghurst, New South Wales, Australia
5Laboratory of Pathology, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland

Tóm tắt

Background: Colorectal cancer is one of the most common and significant malignancies in the world. YKL-40 (chitinase-3-like protein 1) is involved in cell proliferation, migration, inflammation, and tissue remodeling; and serum levels of YKL-40 are associated with patient outcome in various cancers. The aim of this study was to assess the potential clinical usage of YKL-40 pretreatment serum levels as a prognostic biomarker in rectal cancer. Methods: Concentrations of YKL-40 and standard tumor marker—Carcinoembryonic antigen (CEA)—were assessed in serum of 83 patients with rectal cancer without distant metastasis, and association with clinicopathological characteristics and disease-free and overall survival was evaluated. Results: Concentration of YKL-40 was significantly higher in serum of patients with rectal cancer compared to healthy controls ( P = .0001), and YKL-40 levels were able to predict rectal cancer (area under the Receiver Operating Characteristic [ROC] curve = .769) with higher accuracy than CEA (area under the ROC curve = .728) in patients with early stage disease. Increased YKL-40 levels were significantly associated with age ( P = .001); however, no association with other clinicopathological characteristics was observed. Finally, in patients with recurrence, the percentage of cases with increased concentration of YKL-40 was significantly higher than in patients without recurrence ( P = .041), and Kaplan-Meier analysis demonstrated that elevated YKL-40 concentration is a predictor of poor overall survival in patients with rectal cancer. Conclusion: Pretreatment serum levels of YKL-40 may be a novel prognostic factor of overall and disease-free survival in patients with nonmetastatic colorectal cancer.

Từ khóa


Tài liệu tham khảo

10.1002/ijc.29210

10.3322/caac.21220

10.1007/s13277-014-3000-z

Szczepanik AM, 2015, Pol Arch Med Wewn, 125, 443, 10.20452/pamw.2886

10.1053/j.gastro.2015.05.038

10.2217/fon.09.66

10.1369/jhc.7A7245.2007

10.1007/s10735-006-9075-0

10.1158/1055-9965.EPI-05-0011

10.1038/bjc.2011.347

10.1158/1078-0432.CCR-04-1765

Jensen BV, 2003, Clin Cancer Res, 9, 4423

10.1023/A:1024431000710

10.1158/1078-0432.CCR-05-1317

10.1097/CMR.0000000000000237

10.1186/1471-2407-9-8

10.1097/IGC.0000000000000798

10.1097/IGC.0000000000000717

10.1016/j.juro.2015.09.084

10.3390/cancers2031453

10.1200/JCO.2004.09.112

10.1007/s13277-015-3564-2

10.1200/JCO.2005.03.7960

10.1111/joim.12006

10.1038/onc.2009.292

10.1158/1535-7163.MCT-10-0868

10.1074/jbc.M110.212514

10.1530/ERC-14-0267

10.18632/oncotarget.5943

10.3389/fphys.2013.00122

10.1093/carcin/bgt380

10.1158/1055-9965.EPI-13-1281

10.1007/s12032-014-0085-6

10.1038/sj.bjc.6690238

10.1002/cncr.10644

10.1038/onc.2011.498

10.1007/s10151-014-1193-1

10.1371/journal.pone.0087746

10.1371/journal.pone.0123759

Thông tin
Thông tin xuất bản

Technology in Cancer Research and Treatment

Tập 17

Thông tin tác giả